{"date":"2026-04-26","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6589-2026-04-26-2357-1cb645s","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2026-04-26","time":"23:57:32","subject":"本公司授權夥伴Sandoz已向歐洲藥品管理局（EMA）提交生物相似藥EG12014（trastuzumab biosimilar）之變更申請，除已核准劑量包裝150mg vial，將新增420mg vial 劑量包裝","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2026-04-26 23:57，「本公司授權夥伴Sandoz已向歐洲藥品管理局（EMA）提交生物相似藥EG12014（trastuzumab biosim」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2026-04-26-2052-8ih4m5","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2026-04-26","time":"20:52:18","subject":"本公司網路資安事件說明","clause":"第21款","fact_date":"2026-04-24","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2026-04-26 20:52，「本公司網路資安事件說明」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}